🔗 Share this article

Given that the US undertakes unprecedented adjustments to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations during the pandemic and has focused upon potential fatalities following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Program

Health officials were set to announce major revisions to the pediatric immunization program recently, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would put the US at odds with many the international standard with insufficient data for benefit. This reveal has been delayed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A New Direction at the Regulatory Body

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending certain pediatric shot schedules in the US so as to align more like Denmark's approach, a society with universal health coverage and a population approximately the size of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.

Concerns Over Expertise

The appointee has no apparent track record in drug development, regulation or management, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She has no expertise in industry regulation.”

Past commissioners of the center would “understand regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who ran CBER have had.”

CDER has an immense portfolio at the FDA, Woodcock stated.

“Everybody just zeroes in on the new drug program, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and each of these need to be supervised,” Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management aspect to the role, which supervises more than 5,000 employees. “It is a massive management job, if you do it right,” the former official concluded.

Agency Reaction and Contentious Policies

In response to concerns about Dr. Høeg's credentials and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a representative stated that the “inquiries stem from incorrect premises”.

“This background aligns with the responsibilities of her job,” the official stated, noting the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a disputed expedited therapy clearance system that reportedly worried her predecessors. “By what process are these therapies being selected for this voucher program? Who takes the decisions?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent oversight of pharmaceuticals, except for shots.”

Documented History on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, history, Howard observe. She published a study using unverified volunteer-provided data to determine the incidence of myocarditis following COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are riskier than they are.

Part of her “policy goals” for the current administration encompassed altering rules for recently developed shots and halting “non-essential” vaccines, she said after the election on a podcast. At the agency, Høeg has allegedly suggested preventing adolescent males from getting COVID-19 vaccinations.

“She’s an all-around dogmatist who starts off with her preconceived notions and works backwards to retrofit the science in a highly disingenuous, untruthful manner,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|